TNFRSF10B polymorphisms and haplotypes associated with increased risk of death in non-small cell lung cancer
Authors:
- Matthew B. SchabathMSMatthew B. Schabath
- Anna R. GiulianoAGAnna R. Giuliano
- Ernest K. AmankwahEAErnest K. Amankwah
- Kristen A. JonathanKJKristen A. Jonathan
Open Access
- 9 July 2013
- journal article
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 34 (11) , 2525-2530
Abstract
Presently, there are few validated biomarkers that can predict survival or treatment response for non-small cell lung cancer (NSCLC) and most are based on tumor markers. Biomarkers based on germ line DNA variations represent a valuable complementary strategy, which could have translational implications by subclassifying patients to tailored, patient-specific treatment. We analyzed single nucleotide polymorphisms (SNPs) in 53 inflammation-related genes among 651 NSCLC patients. Multivariable Cox proportional hazard models, adjusted for lung cancer prognostic factors, were used to assess the association of genotypes and haplotypes with overall survival. Four of the top 15 SNPs associated with survival were located in the TNF-receptor superfamily member 10b (TNFRSF10B) gene. The T-allele of the top ranked SNP (rs11785599) was associated with a 41% increased risk of death (95% confidence interval [CI] = 1.16–1.70) and the other three TNFRSF10B SNPs (rs1047275, rs4460370 and rs883429) exhibited a 35% (95% CI = 1.11–1.65), 29% (95% CI = 1.06–1.57) and 24% (95% CI = 0.99–1.54) increased risk of death, respectively. Haplotype analyses revealed that the most common risk haplotype (TCTT) was associated with a 78% (95% CI = 1.25–2.54) increased risk of death compared with the low-risk haplotype (CGCC). When the data were stratified by treatment, the risk haplotypes exhibited statistically significantly increased risk of death among patients who had surgery only and no statistically significant effects among patients who had surgery and adjuvant chemotherapy. These data suggest that possessing one or more risk alleles in TNFRSF10B is associated with an increased risk of death. Validated germ line biomarkers may have potential important clinical implications by optimizing patient-specific treatment.Keywords
This publication has 45 references indexed in Scilit:
- miR‐493 induction during carcinogenesis blocks metastatic settlement of colon cancer cells in liverThe EMBO Journal, 2012
- Genome-Wide Association Study of Survival in Non–Small Cell Lung Cancer Patients Receiving Platinum-Based ChemotherapyJNCI: Journal of the National Cancer Institute, 2011
- Evolutionary evidence of the effect of rare variants on disease etiologyClinical Genetics, 2010
- Predominant antitumor effects by fully human anti-TRAIL-receptor2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivoNeuro-Oncology, 2010
- Role of Inflammation Gene Polymorphisms on Pain Severity in Lung Cancer PatientsCancer Epidemiology, Biomarkers & Prevention, 2009
- SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studiesNucleic Acids Research, 2009
- miRBase: tools for microRNA genomicsNucleic Acids Research, 2007
- F-SNP: computationally predicted functional SNPs for disease association studiesNucleic Acids Research, 2007
- Cytokines in cancer pathogenesis and cancer therapyNature Reviews Cancer, 2004
- The Human Genome Browser at UCSCGenome Research, 2002